Dymista may be used to treat allergic rhinitis

draft
The National Health System (SNS) is Financing of DiMista, from Viatris, for the treatment of allergic rhinitis. SNS, which retails for €15.61, ensures more people have access to this first-line treatment and helps control nasal and eye symptoms in people living with the disease.

Allergic rhinitis is a pathology that causes inflammation of the nasal mucosa and is the most common allergic disease in my country. It affects more than 20% of the Spanish population, especially young people, and the most common causes are pollen and dust mites.In this sense, allergists Dr. Juan Manman Igea has explained that “The incidence of this type of rhinitis is very high in Western countries due to our lifestyle. A lack of infection, antibiotics, diet or pollution contributes to a huge increase in allergic diseases every year. “

The drug’s price will give allergic rhinitis patients greater access to this first-line treatment

Specifically, the number of allergy patients in our country increased by 42% between 2016 and 2021, according to the Primary Care Clinical Database. Therefore, studies conducted by Spanish allergists show that, as Dr. Igea states, ““The most common inquiries are due to cases of allergic rhinitis, as this is a chronic condition that affects a large proportion of the population.”

In this sense, the Spanish Society of Otolaryngology and Head and Neck Surgery (Seorl) estimates that the global prevalence of allergic rhinitis ranges from 20% to 40%. The disease is characterized by sneezing, watery eyes, runny nose, and partial or complete loss of smell. There are many factors that contribute to the development of allergic rhinitis, and research continues. However, the lifestyle of Western society is one of the biggest triggers, since limited contact with allergens present in nature affects the strength of the immune system and favors the development of this pathology. In addition, environmental pollution facilitates the spread of allergens.

The lifestyle habits of the Western world can have a negative impact, especially on those with a genetic predisposition to developing allergic diseases. These people successively develop different pathologies, forming their own course of atopy, in which dermatitis is common initially, followed by allergies to certain foods, rhinitis, and finally asthma.

Seorl estimates the global prevalence of allergic rhinitis at 20% to 40%

The effects of this type of rhinitis greatly affect our daily lives.In the words of Dr. Igea, “IAllergic rhinitis is associated with a greater decrease in quality of life than other more serious conditions such as diabetes. Shortness of breath, congestion, or headaches throughout the day make it a very annoying condition. “

.

Therefore, appropriate treatment is necessary to halt its progression. Regarding this issue, Dr. Juan Manuel Igea emphasized that “If left untreated and the disease progresses, we may develop a number of infectious complications, such as bronchitis or sinusitis. “Now we have very safe and effective medications to control allergic rhinitis and prevent it from turning into other more serious conditions like asthma.”.